Avastin and Tarceva for Locally Advanced or Metastatic Non-Squamous Non-Small-Cell Lung Cancer

Inclusion Criteria:

* Patient has histologically proven stage IIIB with pleural effusion, stage IV or recurrent non-squamous NSCLC.
* Patient has a Karnofsky performance status \>=70%.
* Patient has adequate bone marrow function: WBC \>= 3,000 cells/mm3, ANC \>= 1,500 cells/mm3, platelet count \>= 100,000 cells/mm3, Hgb \>= 9.0 g/dL.
* Patient has adequate liver function: total bilirubin level \<= 2.0 mg/dL, albumin \>= 2.5 g/dL.
* Transaminases (aspartate aminotransferase (AST or SGOT) and/or alanine aminotransferase (ALT or SGPT)) and alkaline phosphatase may be up to 2.5 x ULN.
* Patient has adequate renal function: a serum creatinine \< 2 mg/dl
* Patient has signed a written informed consent.
* Patient has received at least one prior chemotherapeutic regimen for recurrent or metastatic disease.

Exclusion Criteria:

* Patient has not received prior chemotherapeutic regimens for advanced disease.
* Patient has received prior biologic therapy targeting epidermal growth factor receptor (EGFR) and/or Vascular endothelial growth factor (VEGF).
* Patient has received radiation therapy within the past 3 weeks.
* Patient has signs or symptoms of acute infection requiring systemic therapy.
* Patient exhibits confusion, disorientation, or has a history of major psychiatric illness that may impair patient's understanding of the informed consent.
* Patient requires total parenteral nutrition with lipids.
* Patient has a history of uncontrolled heart disease and/or uncontrolled hypertension (\> 150/100 mmHg).
* Because of the possible teratogenic effect, pregnant women and women who are currently breast-feeding may not participate in this study. - All women of childbearing potential must have a negative pregnancy test within 24 hours prior to enrolling in the study.
* Serious infection or other intercurrent illness requiring immediate therapy.
* Clinical/imaging evidence of Central Nervous System (CNS) malignancy or with recently treated CNS malignancy, as well as those experiencing recent cerebrovascular accident (CVA), or other CNS bleeding.
* Pediatric patients in whom open growth plates would be expected.
* Urine protein qualitative value of \> 30 in urinalysis or \> +1 in proteinuria testing by dipstick.
* Patient has a clinical history of coagulopathy or thrombosis.
* Patient is currently receiving or intending to receive anti-coagulants.
* Patient has had a recent myocardial infarction (still inside the healing period). Note: a six-month window is optimal.
* Patient is recovering from recent major surgery (e.g., less than 2 weeks since surgery) or is anticipating major surgery.
* Patient has a clinical history of hemoptysis or hematemesis.
* Patient may not have percutaneous endoscopic gastrostomy (PEG) or gastrostomy (G) tube.